CalciMedica Reports 2024 Financial Results and Provides Clinical & Corporate Updates
Provided By PR Newswire
Last update: Mar 27, 2025
Enrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) and respiratory failure; data expected around the end of 2025
Post-hoc analysis of subset of patients with AKI in the Phase 2 CARDEA trial of Auxora in severe COVID-19 pneumonia showed a 62.7% relative reduction in mortality at day 30, which persisted through day 60, for patients treated with Auxora versus placebo
Read more at prnewswire.com
